Cell Line Development Market by Product (Equipment, Media and Reagents), Source, type & by Application ( Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) - Analysis & Global Forecast to 2019
Over the years, the cell line development market has witnessed various technological advancements in order to cater to the growing demand for stable and high-yielding cell lines. These advancements have led to growth in a number of applications of cell lines such as bioproduction, tissue engineering and regenerative medicine, toxicity testing, research, and drug discovery.
Cell line development media and reagents account for the largest share in the global cell line development market, as they have numerous applications in areas such as bioproduction, tissue engineering and regenerative medicine, toxicity testing, research, and drug discovery. The reagents segment accounted for the maximum share of the cell line development media and reagents market. The bioproduction segment accounted for the largest share of the cell line development application market, as cell lines are extensively used in diagnostics, vaccine production, and in manufacturing of recombinant protein therapeutics.
North America accounted for the largest share of the global cell line development market, followed by Europe, Asia, and the Rest of the World (RoW). In the coming years, the cell line development market is expected to experience the highest growth rate in the Asian region, with emphasis on India, China, and Japan. These countries are expected to serve as revenue pockets for cell line manufacturers.
The global cell line development market witnesses high competitive intensity as there are several big and many small firms with similar product offerings. These companies adopt various strategies (innovations, acquisitions, and geographical expansions) to increase their market shares and to establish a strong foothold in the global market.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
Cell line development media and reagents account for the largest share in the global cell line development market, as they have numerous applications in areas such as bioproduction, tissue engineering and regenerative medicine, toxicity testing, research, and drug discovery. The reagents segment accounted for the maximum share of the cell line development media and reagents market. The bioproduction segment accounted for the largest share of the cell line development application market, as cell lines are extensively used in diagnostics, vaccine production, and in manufacturing of recombinant protein therapeutics.
North America accounted for the largest share of the global cell line development market, followed by Europe, Asia, and the Rest of the World (RoW). In the coming years, the cell line development market is expected to experience the highest growth rate in the Asian region, with emphasis on India, China, and Japan. These countries are expected to serve as revenue pockets for cell line manufacturers.
The global cell line development market witnesses high competitive intensity as there are several big and many small firms with similar product offerings. These companies adopt various strategies (innovations, acquisitions, and geographical expansions) to increase their market shares and to establish a strong foothold in the global market.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios and services offered by the top players in the cell line development market. The report analyzes cell line development products by equipment and media and reagents
- Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the cell line development market
- Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various cell line development technologies across geographies
- Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the cell line development market
- Competitive Assessment: In-depth assessment of the market shares, strategies, products and services, distribution networks, and manufacturing capabilities of the leading players in the cell line development market
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET SCOPE
1.3 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 SECONDARY AND PRIMARY RESEARCH METHODOLOGY
2.1.1 SECONDARY RESEARCH
2.1.1.1 key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Key Industry Insights
2.1.2.2 key data from primary sources
2.1.2.3 key Insights from primary sources
2.1.3 MARKET SIZE ESTIMATION METHODOLOGY
2.1.4 MARKET FORECAST METHODOLOGY
2.1.5 MARKET DATA VALIDATION AND DATA TRIANGULATION
2.1.6 ASSUMPTIONS
2.1.7 LIMITATIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 GLOBAL CELL LINE DEVELOPMENT MARKET SIZE
4.2 CELL LINE DEVELOPMENT MARKET, BY GEOGRAPHY AND TYPE
4.3 GEOGRAPHICAL SNAPSHOT
4.4 MARKET SHARE, BY PRODUCT
4.5 LIFE CYCLE ANALYSIS, BY GEOGRAPHY
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Global increase in demand for monoclonal antibodies
5.2.1.2 Innovative technologies accelerating the scale-up of cell lines
5.2.1.3 Rise in vaccine production
5.2.2 CHALLENGES
5.2.2.1 Developing sTable and authentic cell lines
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing risk of pandemics and communicable diseases
5.2.3.2 Low-income countries to create opportunities for the cell line development market
6 INDUSTRY INSIGHTS
6.1 INTRODUCTION
6.2 COMPETITIVE POSITIONING, BY KEY PLAYER (2014)
6.2.1 INTRODUCTION
6.2.2 KEY HIGHLIGHTS
6.3 CELL LINE DEVELOPMENT MARKET: EMPIRICAL ASSESSMENT OF GROWTH STRATEGIES
6.3.1 ROUTE TO STRATEGIC GROWTH: ORGANIC OR INORGANIC GROWTH
6.3.2 ORGANIC GROWTH STRATEGIES
6.3.3 INORGANIC GROWTH STRATEGIES
6.4 TECHNOLOGY ASSESSMENT
6.4.1 EXPRESSION SYSTEMS
6.4.1.1 Methotrexate Amplification (DHFR) Technology
6.4.1.2 Glutamine Synthatase (GS) Technology
6.4.1.3 Viral-based Technology
7 GLOBAL CELL LINE DEVELOPMENT MARKET, BY PRODUCT
7.1 CELL LINE DEVELOPMENT MARKET, BY PRODUCT
7.2 GLOBAL CELL LINE DEVELOPMENT MARKET, BY EQUIPMENT
7.2.1 INTRODUCTION
7.2.2 BIOSAFETY CABINETS
7.2.3 CELL COUNTERS & VIABILITY ANALYSIS SYSTEMS
7.2.4 INCUBATORS
7.2.5 CENTRIFUGES
7.2.6 BIOREACTORS
7.2.7 STORAGE EQUIPMENT
7.2.7.1 Refrigerators & Freezers
7.2.7.2 Cryostorage Systems
7.2.8 AUTOMATION SYSTEMS
7.2.9 MICROSCOPES
7.2.10 FILTRATION SYSTEMS
7.2.11 OTHER EQUIPMENT
7.3 GLOBAL CELL LINE DEVELOPMENT MARKET, BY MEDIA & REAGENTS
7.3.1 INTRODUCTION
7.3.2 CELL LINE MEDIA & REAGENTS
7.3.2.1 Sera
7.3.2.1.1 Fetal Bovine Sera (FBS)
7.3.2.1.2 Adult Bovine Sera (ABS)
7.3.2.1.3 Other Animal Sera
7.3.2.2 Media
7.3.2.2.1 Minimum Essential Media (MEM)
7.3.2.2.2 Reduced Serum Media
7.3.2.2.3 Serum-Free Media (SFM)
7.3.2.3 REAGENTS
7.3.2.3.1 Supplements & Growth Factors
7.3.2.3.2 Buffers & Chemicals
7.3.2.3.3 Cell Dissociation Reagents
7.3.2.3.4 Cryopreservative Reagents
7.3.2.3.5 Other Reagents
8 CELL LINE DEVELOPMENT MARKET, BY SOURCE
8.1 INTRODUCTION
8.1.1 MAMMALIAN
8.1.2 INSECT
8.1.3 AMPHIBIAN
9 CELL LINE DEVELOPMENT MARKET, BY TYPE
9.1 INTRODUCTION
9.1.1 PRIMARY CELL LINES
9.1.2 CONTINUOUS CELL LINES
9.1.3 HYBRIDOMAS
9.1.4 RECOMBINANT CELL LINES
10 GLOBAL CELL LINE DEVELOPMENT MARKET, BY APPLICATION
10.1 INTRODUCTION
10.2 BIOPRODUCTION
10.2.1 DIAGNOSTICS
10.2.2 VACCINE PRODUCTION
10.2.3 RECOMBINANT PROTEIN THERAPEUTICS
10.3 TISSUE ENGINEERING & REGENERATIVE MEDICINE
10.4 TOXICITY TESTING
10.5 RESEARCH
10.6 DRUG DISCOVERY
10.6.1 TARGET VALIDATION
10.6.2 DISEASE MODELING
10.6.3 DRUG SCREENING AND DEVELOPMENT
11 CELL LINE DEVELOPMENT MARKET, BY GEOGRAPHY
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 U.S.
11.2.1.1 R&D Investments by Pharmaceutical Companies in the U.S. to Propel the Cell Line Development Market
11.2.1.2 Rise in Funding for Vaccine Production likely to Fuel Demand of Cell Line Development Market
11.2.1.3 Conferences on Cell Line Development to Propel Growth of Market
11.2.2 CANADA
11.2.2.1 Increasing Investments on Regenerative Medicines by Canadian Government to Spur the Market
11.3 EUROPE
11.3.1 FLOURISHING VACCINE MARKET IN EUROPE—A MAJOR PROPELLANT FOR THE CELL LINE DEVELOPMENT MARKET
11.3.2 FRANCE
11.3.2.1 Increasing Use of Cell Lines for Vaccine Production to Spur Market in France
11.3.3 GERMANY
11.3.3.1 Advances in Biotechnology Fueling the Cell Line Development Market in Germany
11.3.4 U.K.
11.3.4.1 Conferences on Cell Line Development to Spur Market in the U.K.
11.3.5 REST OF EUROPE (ROE)
11.3.5.1 Increasing Research on Regenerative Medicines in Spain to Propel the Cell Line Development Market
11.4 ASIA
11.4.1 INDIA
11.4.1.1 Growing Pharmaceutical Industry to Propel the Market in India
11.4.2 CHINA
11.4.2.1 Developing Pharmaceutical Industry to Spur the Market in China
11.4.3 JAPAN
11.4.3.1 Rise in Production of Vaccines in Japan to Propel the Use of Cell Lines
11.4.3.2 Regenerative Medicine, Biomedical, and Medical Research in Japan is on the Rise
11.4.4 REST OF ASIA (ROA)
11.4.4.1 Initiation of Measles-Rubella Combined Vaccine Production in Vietnam
11.4.4.2 Government-Supported Strong Academic and Commercial R&D Activities in Taiwan
11.5 REST OF THE WORLD (ROW)
11.5.1 PACIFIC COUNTRIES
11.5.1.1 Federal Collaborations in Australia to Bolster the Demand of Cell Lines
11.5.1.2 Favorable Regulatory Changes to Drive the Market in New Zealand and Australia
11.5.2 BRAZIL
11.5.2.1 Flourishing Biotechnology and Pharmaceutical Markets in Brazil to Bolster the Cell Line Development Market
11.5.3 AFRICA
11.5.3.1 Increasing Focus on Africa by Pharmaceutical Companies Likely to Create Avenues for Cell Line Development Market
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 MARKET SHARE ANALYSIS, CELL LINE DEVELOPMENT MARKET
12.2.1 INTRODUCTION
12.2.1.1 American Type Culture Collection (ATCC) (U.S.)
12.2.1.2 Lonza Group AG (Switzerland)
12.2.1.3 Thermo Fisher Scientific, Inc. (U.S.)
12.3 COMPETITIVE SITUATION AND TRENDS
12.3.1 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
12.3.2 NEW PRODUCT LAUNCHES
12.3.3 EXPANSIONS
12.3.4 ACQUISITIONS
12.3.5 OTHERS
13 COMPANY PROFILES (OVERVIEW, FINANCIALS, PRODUCTS & SERVICES, STRATEGY, & DEVELOPMENTS)
13.1 INTRODUCTION
13.2 AMERICAN TYPE CULTURE COLLECTION (ATCC)
13.3 CORNING, INC.
13.4 EUROPEAN COLLECTION OF CELL CULTURES (ECACC)
13.5 GE HEALTHCARE
13.6 LONZA GROUP AG
13.7 SARTORIUS AG
13.8 SELEXIS SA
13.9 SIGMA-ALDRICH CORPORATION
13.10 THERMO FISHER SCIENTIFIC, INC.
13.11 WUXI APPTEC (Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.)
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 INTRODUCING RT: REAL TIME MARKET INTELLIGENCE
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET SCOPE
1.3 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 SECONDARY AND PRIMARY RESEARCH METHODOLOGY
2.1.1 SECONDARY RESEARCH
2.1.1.1 key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Key Industry Insights
2.1.2.2 key data from primary sources
2.1.2.3 key Insights from primary sources
2.1.3 MARKET SIZE ESTIMATION METHODOLOGY
2.1.4 MARKET FORECAST METHODOLOGY
2.1.5 MARKET DATA VALIDATION AND DATA TRIANGULATION
2.1.6 ASSUMPTIONS
2.1.7 LIMITATIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 GLOBAL CELL LINE DEVELOPMENT MARKET SIZE
4.2 CELL LINE DEVELOPMENT MARKET, BY GEOGRAPHY AND TYPE
4.3 GEOGRAPHICAL SNAPSHOT
4.4 MARKET SHARE, BY PRODUCT
4.5 LIFE CYCLE ANALYSIS, BY GEOGRAPHY
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Global increase in demand for monoclonal antibodies
5.2.1.2 Innovative technologies accelerating the scale-up of cell lines
5.2.1.3 Rise in vaccine production
5.2.2 CHALLENGES
5.2.2.1 Developing sTable and authentic cell lines
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing risk of pandemics and communicable diseases
5.2.3.2 Low-income countries to create opportunities for the cell line development market
6 INDUSTRY INSIGHTS
6.1 INTRODUCTION
6.2 COMPETITIVE POSITIONING, BY KEY PLAYER (2014)
6.2.1 INTRODUCTION
6.2.2 KEY HIGHLIGHTS
6.3 CELL LINE DEVELOPMENT MARKET: EMPIRICAL ASSESSMENT OF GROWTH STRATEGIES
6.3.1 ROUTE TO STRATEGIC GROWTH: ORGANIC OR INORGANIC GROWTH
6.3.2 ORGANIC GROWTH STRATEGIES
6.3.3 INORGANIC GROWTH STRATEGIES
6.4 TECHNOLOGY ASSESSMENT
6.4.1 EXPRESSION SYSTEMS
6.4.1.1 Methotrexate Amplification (DHFR) Technology
6.4.1.2 Glutamine Synthatase (GS) Technology
6.4.1.3 Viral-based Technology
7 GLOBAL CELL LINE DEVELOPMENT MARKET, BY PRODUCT
7.1 CELL LINE DEVELOPMENT MARKET, BY PRODUCT
7.2 GLOBAL CELL LINE DEVELOPMENT MARKET, BY EQUIPMENT
7.2.1 INTRODUCTION
7.2.2 BIOSAFETY CABINETS
7.2.3 CELL COUNTERS & VIABILITY ANALYSIS SYSTEMS
7.2.4 INCUBATORS
7.2.5 CENTRIFUGES
7.2.6 BIOREACTORS
7.2.7 STORAGE EQUIPMENT
7.2.7.1 Refrigerators & Freezers
7.2.7.2 Cryostorage Systems
7.2.8 AUTOMATION SYSTEMS
7.2.9 MICROSCOPES
7.2.10 FILTRATION SYSTEMS
7.2.11 OTHER EQUIPMENT
7.3 GLOBAL CELL LINE DEVELOPMENT MARKET, BY MEDIA & REAGENTS
7.3.1 INTRODUCTION
7.3.2 CELL LINE MEDIA & REAGENTS
7.3.2.1 Sera
7.3.2.1.1 Fetal Bovine Sera (FBS)
7.3.2.1.2 Adult Bovine Sera (ABS)
7.3.2.1.3 Other Animal Sera
7.3.2.2 Media
7.3.2.2.1 Minimum Essential Media (MEM)
7.3.2.2.2 Reduced Serum Media
7.3.2.2.3 Serum-Free Media (SFM)
7.3.2.3 REAGENTS
7.3.2.3.1 Supplements & Growth Factors
7.3.2.3.2 Buffers & Chemicals
7.3.2.3.3 Cell Dissociation Reagents
7.3.2.3.4 Cryopreservative Reagents
7.3.2.3.5 Other Reagents
8 CELL LINE DEVELOPMENT MARKET, BY SOURCE
8.1 INTRODUCTION
8.1.1 MAMMALIAN
8.1.2 INSECT
8.1.3 AMPHIBIAN
9 CELL LINE DEVELOPMENT MARKET, BY TYPE
9.1 INTRODUCTION
9.1.1 PRIMARY CELL LINES
9.1.2 CONTINUOUS CELL LINES
9.1.3 HYBRIDOMAS
9.1.4 RECOMBINANT CELL LINES
10 GLOBAL CELL LINE DEVELOPMENT MARKET, BY APPLICATION
10.1 INTRODUCTION
10.2 BIOPRODUCTION
10.2.1 DIAGNOSTICS
10.2.2 VACCINE PRODUCTION
10.2.3 RECOMBINANT PROTEIN THERAPEUTICS
10.3 TISSUE ENGINEERING & REGENERATIVE MEDICINE
10.4 TOXICITY TESTING
10.5 RESEARCH
10.6 DRUG DISCOVERY
10.6.1 TARGET VALIDATION
10.6.2 DISEASE MODELING
10.6.3 DRUG SCREENING AND DEVELOPMENT
11 CELL LINE DEVELOPMENT MARKET, BY GEOGRAPHY
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 U.S.
11.2.1.1 R&D Investments by Pharmaceutical Companies in the U.S. to Propel the Cell Line Development Market
11.2.1.2 Rise in Funding for Vaccine Production likely to Fuel Demand of Cell Line Development Market
11.2.1.3 Conferences on Cell Line Development to Propel Growth of Market
11.2.2 CANADA
11.2.2.1 Increasing Investments on Regenerative Medicines by Canadian Government to Spur the Market
11.3 EUROPE
11.3.1 FLOURISHING VACCINE MARKET IN EUROPE—A MAJOR PROPELLANT FOR THE CELL LINE DEVELOPMENT MARKET
11.3.2 FRANCE
11.3.2.1 Increasing Use of Cell Lines for Vaccine Production to Spur Market in France
11.3.3 GERMANY
11.3.3.1 Advances in Biotechnology Fueling the Cell Line Development Market in Germany
11.3.4 U.K.
11.3.4.1 Conferences on Cell Line Development to Spur Market in the U.K.
11.3.5 REST OF EUROPE (ROE)
11.3.5.1 Increasing Research on Regenerative Medicines in Spain to Propel the Cell Line Development Market
11.4 ASIA
11.4.1 INDIA
11.4.1.1 Growing Pharmaceutical Industry to Propel the Market in India
11.4.2 CHINA
11.4.2.1 Developing Pharmaceutical Industry to Spur the Market in China
11.4.3 JAPAN
11.4.3.1 Rise in Production of Vaccines in Japan to Propel the Use of Cell Lines
11.4.3.2 Regenerative Medicine, Biomedical, and Medical Research in Japan is on the Rise
11.4.4 REST OF ASIA (ROA)
11.4.4.1 Initiation of Measles-Rubella Combined Vaccine Production in Vietnam
11.4.4.2 Government-Supported Strong Academic and Commercial R&D Activities in Taiwan
11.5 REST OF THE WORLD (ROW)
11.5.1 PACIFIC COUNTRIES
11.5.1.1 Federal Collaborations in Australia to Bolster the Demand of Cell Lines
11.5.1.2 Favorable Regulatory Changes to Drive the Market in New Zealand and Australia
11.5.2 BRAZIL
11.5.2.1 Flourishing Biotechnology and Pharmaceutical Markets in Brazil to Bolster the Cell Line Development Market
11.5.3 AFRICA
11.5.3.1 Increasing Focus on Africa by Pharmaceutical Companies Likely to Create Avenues for Cell Line Development Market
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 MARKET SHARE ANALYSIS, CELL LINE DEVELOPMENT MARKET
12.2.1 INTRODUCTION
12.2.1.1 American Type Culture Collection (ATCC) (U.S.)
12.2.1.2 Lonza Group AG (Switzerland)
12.2.1.3 Thermo Fisher Scientific, Inc. (U.S.)
12.3 COMPETITIVE SITUATION AND TRENDS
12.3.1 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
12.3.2 NEW PRODUCT LAUNCHES
12.3.3 EXPANSIONS
12.3.4 ACQUISITIONS
12.3.5 OTHERS
13 COMPANY PROFILES (OVERVIEW, FINANCIALS, PRODUCTS & SERVICES, STRATEGY, & DEVELOPMENTS)
13.1 INTRODUCTION
13.2 AMERICAN TYPE CULTURE COLLECTION (ATCC)
13.3 CORNING, INC.
13.4 EUROPEAN COLLECTION OF CELL CULTURES (ECACC)
13.5 GE HEALTHCARE
13.6 LONZA GROUP AG
13.7 SARTORIUS AG
13.8 SELEXIS SA
13.9 SIGMA-ALDRICH CORPORATION
13.10 THERMO FISHER SCIENTIFIC, INC.
13.11 WUXI APPTEC (Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.)
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 INTRODUCING RT: REAL TIME MARKET INTELLIGENCE
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
LIST OF TABLES
Table 1 DRIVERS PROPELLING THE GROWTH OF THE CELL LINE DEVELOPMENT MARKET
Table 2 MAJOR CHALLENGE IN THE CELL LINE DEVELOPMENT MARKET
Table 3 MAJOR GROWTH OPPORTUNITIES IN THE CELL LINE DEVELOPMENT MARKET
Table 4 CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 5 CELL LINE DEVELOPMENT MARKET SIZE FOR EQUIPMENT, BY REGION, 2012–2019 ($MILLION)
Table 6 CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2012–2019 ($MILLION)
Table 7 CELL LINE DEVELOPMENT MARKET SIZE FOR BIOSAFETY CABINETS, BY REGION, 2012–2019 ($MILLION)
Table 8 CELL LINE DEVELOPMENT MARKET SIZE FOR CELL COUNTERS & VIABILITY ANALYSIS SYSTEMS, BY REGION, 2012–2019 ($MILLION)
Table 9 CELL LINE DEVELOPMENT MARKET SIZE FOR INCUBATORS, BY REGION, 2012–2019 ($MILLION)
Table 10 CELL LINE DEVELOPMENT MARKET SIZE FOR CENTRIFUGES, BY REGION, 2012–2019 ($MILLION)
Table 11 CELL LINE DEVELOPMENT MARKET SIZE FOR BIOREACTORS, BY REGION, 2012–2019 ($MILLION)
Table 12 CELL LINE DEVELOPMENT MARKET SIZE FOR STORAGE EQUIPMENT, BY REGION, 2012–2019 ($MILLION)
Table 13 CELL LINE DEVELOPMENT MARKET SIZE FOR STORAGE EQUIPMENT, BY SEGMENT, 2012–2019 ($MILLION)
Table 14 CELL LINE DEVELOPMENT MARKET SIZE FOR REFRIGERATORS & FREEZERS, BY REGION, 2012–2019 ($MILLION)
Table 15 CELL LINE DEVELOPMENT MARKET SIZE FOR CRYOSTORAGE SYSTEMS, BY REGION, 2012–2019 ($MILLION)
Table 16 CELL LINE DEVELOPMENT MARKET SIZE FOR AUTOMATION SYSTEMS, BY REGION, 2012–2019 ($MILLION)
Table 17 CELL LINE DEVELOPMENT MARKET SIZE FOR MICROSCOPES, BY REGION, 2012–2019 ($MILLION)
Table 18 CELL LINE DEVELOPMENT MARKET SIZE FOR FILTRATION SYSTEMS, BY REGION, 2012–2019 ($MILLION)
Table 19 CELL LINE DEVELOPMENT MARKET SIZE FOR OTHER EQUIPMENT, BY REGION, 2012–2019 ($MILLION)
Table 20 CELL LINE DEVELOPMENT MARKET SIZE FOR MEDIA & REAGENTS, BY SEGMENT, 2012–2019 ($MILLION)
Table 21 CELL LINE DEVELOPMENT MARKET SIZE FOR MEDIA & REAGENTS, BY REGION, 2012–2019 ($MILLION)
Table 22 CELL LINE DEVELOPMENT MARKET SIZE FOR SERA, BY REGION, 2012–2019 ($MILLION)
Table 23 CELL LINE DEVELOPMENT MARKET SIZE FOR SERA, BY SEGMENT, 2012–2019 ($MILLION)
Table 24 CELL LINE DEVELOPMENT MARKET SIZE FOR FETAL BOVINE SERA, BY REGION, 2012–2019 ($MILLION)
Table 25 CELL LINE DEVELOPMENT MARKET SIZE FOR ADULT BOVINE SERA, BY REGION, 2012–2019 ($MILLION)
Table 26 CELL LINE DEVELOPMENT MARKET SIZE FOR OTHER ANIMAL SERA, BY REGION, 2012–2019 ($MILLION)
Table 27 CELL LINE DEVELOPMENT MARKET SIZE FOR MEDIA, BY REGION, 2012–2019 ($MILLION)
Table 28 CELL LINE DEVELOPMENT MARKET SIZE FOR MEDIA, BY SEGMENT, 2012–2019 ($MILLION)
Table 29 CELL LINE DEVELOPMENT MARKET SIZE FOR MINIMUM ESSENTIAL MEDIA, BY REGION, 2012–2019 ($MILLION)
Table 30 CELL LINE DEVELOPMENT MARKET SIZE FOR REDUCED SERUM MEDIA, BY REGION, 2012–2019 ($MILLION)
Table 31 CELL LINE DEVELOPMENT MARKET SIZE FOR SERUM-FREE MEDIA, BY REGION, 2012–2019 ($MILLION)
Table 32 CELL LINE DEVELOPMENT MARKET SIZE FOR REAGENTS, BY REGION, 2012–2019 ($MILLION)
Table 33 CELL LINE DEVELOPMENT MARKET SIZE FOR REAGENTS, BY SEGMENT, 2012–2019 ($MILLION)
Table 34 CELL LINE DEVELOPMENT MARKET SIZE FOR SUPPLEMENTS & GROWTH FACTORS, BY REGION, 2012–2019 ($MILLION)
Table 35 CELL LINE DEVELOPMENT MARKET SIZE FOR BUFFERS & CHEMICALS, BY REGION, 2012–2019 ($MILLION)
Table 36 CELL LINE DEVELOPMENT MARKET SIZE FOR CELL DISSOCIATION REAGENTS, BY REGION, 2012–2019 ($MILLION)
Table 37 CELL LINE DEVELOPMENT MARKET SIZE FOR CRYOPRESERVATIVE REAGENTS, BY REGION, 2012–2019 ($MILLION)
Table 38 CELL LINE DEVELOPMENT MARKET SIZE FOR OTHER REAGENTS, BY REGION, 2012–2019 ($MILLION)
Table 39 CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 40 TYPES OF MAMMALIAN CELL LINES AND THEIR APPLICATIONS
Table 41 CELL LINE DEVELOPMENT MARKET SIZE FOR MAMMALIAN SOURCES, BY REGION, 2012–2019 ($MILLION)
Table 42 CELL LINE DEVELOPMENT MARKET SIZE FOR INSECT SOURCES, BY REGION, 2012–2019 ($MILLION)
Table 43 CELL LINE DEVELOPMENT MARKET SIZE FOR AMPHIBIAN SOURCES, BY REGION, 2012–2019 ($MILLION)
Table 44 CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 45 CELL LINE DEVELOPMENT MARKET SIZE FOR PRIMARY CELL LINES, BY REGION, 2012–2019 ($MILLION)
Table 46 CELL LINE DEVELOPMENT MARKET SIZE FOR CONTINUOUS CELL LINES, BY REGION, 2012–2019 ($MILLION)
Table 47 CELL LINE DEVELOPMENT MARKET SIZE FOR HYBRIDOMAS, BY REGION, 2012–2019 ($MILLION)
Table 48 BIOLOGICS PRODUCED USING CHO CELLS (2006-2012)
Table 49 CELL LINE DEVELOPMENT MARKET SIZE FOR RECOMBINANT CELL LINES, BY REGION, 2012–2019 ($MILLION)
Table 50 CELL LINE DEVELOPMENT APPLICATIONS MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
Table 51 CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 52 CELL LINE DEVELOPMENT MARKET SIZE FOR BIOPRODUCTION, BY REGION, 2012–2019 ($MILLION)
Table 53 CELL LINE DEVELOPMENT MARKET SIZE FOR BIOPRODUCTION, BY SEGMENT, 2012–2019 ($MILLION)
Table 54 CELL LINE DEVELOPMENT MARKET SIZE FOR DIAGNOSTICS, BY REGION, 2012–2019 ($MILLION)
Table 55 CELL LINE DEVELOPMENT MARKET SIZE FOR VACCINE PRODUCTION, BY REGION, 2012–2019 ($MILLION)
Table 56 CELL LINE DEVELOPMENT MARKET SIZE FOR RECOMBINANT PROTEIN THERAPEUTICS, BY REGION, 2012–2019 ($MILLION)
Table 57 CELL LINE DEVELOPMENT MARKET SIZE FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY REGION, 2012–2019 ($MILLION)
Table 58 CELL LINE DEVELOPMENT MARKET SIZE FOR TOXICITY TESTING, BY REGION, 2012–2019 ($MILLION)
Table 59 CELL LINE DEVELOPMENT MARKET SIZE FOR RESEARCH APPLICATIONS, BY REGION, 2012–2019 ($MILLION)
Table 60 CELL LINE DEVELOPMENT MARKET SIZE FOR DRUG DISCOVERY, BY REGION, 2012–2019 ($MILLION)
Table 61 CELL LINE DEVELOPMENT MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
Table 62 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 63 NORTH AMERICA: CELL LINE DEVELOPMENT EQUIPMENT MARKET SIZE, 2012–2019 ($MILLION)
Table 64 NORTH AMERICA: CELL LINE DEVELOPMENT MEDIA & REAGENTS MARKET SIZE, 2012–2019 ($MILLION)
Table 65 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 66 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 67 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 68 U.S.: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 69 U.S.: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 70 U.S.: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 71 U.S.: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 72 CANADA: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 73 CANADA: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 74 CANADA: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 75 CANADA: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 76 EUROPE: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 77 EUROPE: CELL LINE DEVELOPMENT EQUIPMENT MARKET SIZE, 2012–2019 ($MILLION)
Table 78 EUROPE: CELL LINE DEVELOPMENT MEDIA & REAGENTS MARKET SIZE, 2012–2019 ($MILLION)
Table 79 EUROPE: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 80 EUROPE: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 81 EUROPE: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 82 FRANCE: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 83 FRANCE: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 84 FRANCE: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 85 FRANCE: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 86 GERMANY: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 87 GERMANY: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 88 GERMANY: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 89 GERMANY: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 90 U.K.: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 91 U.K.: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 92 U.K.: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 93 U.K.: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 94 ROE: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 95 ROE: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 96 ROE: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 97 ROE: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 98 ASIA: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 99 ASIA: CELL LINE DEVELOPMENT EQUIPMENT MARKET SIZE, 2012–2019 ($MILLION)
Table 100 ASIA: CELL LINE DEVELOPMENT MEDIA & REAGENTS MARKET SIZE, 2012–2019 ($MILLION)
Table 101 ASIA: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 102 ASIA: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 103 ASIA: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 104 ROW: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 105 ROW: CELL LINE DEVELOPMENT EQUIPMENT MARKET SIZE, 2012–2019 ($MILLION)
Table 106 ROW: CELL LINE DEVELOPMENT MEDIA & REAGENTS MARKET SIZE, 2012–2019 ($MILLION)
Table 107 ROW: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 108 ROW: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 109 ROW: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 110 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 2011–2014
Table 111 NEW PRODUCT LAUNCHES, 2011–2013
Table 112 EXPANSIONS, 2011–2014
Table 113 ACQUISITIONS, 2011–2014
Table 114 OTHERS, 2011–2014
Table 1 DRIVERS PROPELLING THE GROWTH OF THE CELL LINE DEVELOPMENT MARKET
Table 2 MAJOR CHALLENGE IN THE CELL LINE DEVELOPMENT MARKET
Table 3 MAJOR GROWTH OPPORTUNITIES IN THE CELL LINE DEVELOPMENT MARKET
Table 4 CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 5 CELL LINE DEVELOPMENT MARKET SIZE FOR EQUIPMENT, BY REGION, 2012–2019 ($MILLION)
Table 6 CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2012–2019 ($MILLION)
Table 7 CELL LINE DEVELOPMENT MARKET SIZE FOR BIOSAFETY CABINETS, BY REGION, 2012–2019 ($MILLION)
Table 8 CELL LINE DEVELOPMENT MARKET SIZE FOR CELL COUNTERS & VIABILITY ANALYSIS SYSTEMS, BY REGION, 2012–2019 ($MILLION)
Table 9 CELL LINE DEVELOPMENT MARKET SIZE FOR INCUBATORS, BY REGION, 2012–2019 ($MILLION)
Table 10 CELL LINE DEVELOPMENT MARKET SIZE FOR CENTRIFUGES, BY REGION, 2012–2019 ($MILLION)
Table 11 CELL LINE DEVELOPMENT MARKET SIZE FOR BIOREACTORS, BY REGION, 2012–2019 ($MILLION)
Table 12 CELL LINE DEVELOPMENT MARKET SIZE FOR STORAGE EQUIPMENT, BY REGION, 2012–2019 ($MILLION)
Table 13 CELL LINE DEVELOPMENT MARKET SIZE FOR STORAGE EQUIPMENT, BY SEGMENT, 2012–2019 ($MILLION)
Table 14 CELL LINE DEVELOPMENT MARKET SIZE FOR REFRIGERATORS & FREEZERS, BY REGION, 2012–2019 ($MILLION)
Table 15 CELL LINE DEVELOPMENT MARKET SIZE FOR CRYOSTORAGE SYSTEMS, BY REGION, 2012–2019 ($MILLION)
Table 16 CELL LINE DEVELOPMENT MARKET SIZE FOR AUTOMATION SYSTEMS, BY REGION, 2012–2019 ($MILLION)
Table 17 CELL LINE DEVELOPMENT MARKET SIZE FOR MICROSCOPES, BY REGION, 2012–2019 ($MILLION)
Table 18 CELL LINE DEVELOPMENT MARKET SIZE FOR FILTRATION SYSTEMS, BY REGION, 2012–2019 ($MILLION)
Table 19 CELL LINE DEVELOPMENT MARKET SIZE FOR OTHER EQUIPMENT, BY REGION, 2012–2019 ($MILLION)
Table 20 CELL LINE DEVELOPMENT MARKET SIZE FOR MEDIA & REAGENTS, BY SEGMENT, 2012–2019 ($MILLION)
Table 21 CELL LINE DEVELOPMENT MARKET SIZE FOR MEDIA & REAGENTS, BY REGION, 2012–2019 ($MILLION)
Table 22 CELL LINE DEVELOPMENT MARKET SIZE FOR SERA, BY REGION, 2012–2019 ($MILLION)
Table 23 CELL LINE DEVELOPMENT MARKET SIZE FOR SERA, BY SEGMENT, 2012–2019 ($MILLION)
Table 24 CELL LINE DEVELOPMENT MARKET SIZE FOR FETAL BOVINE SERA, BY REGION, 2012–2019 ($MILLION)
Table 25 CELL LINE DEVELOPMENT MARKET SIZE FOR ADULT BOVINE SERA, BY REGION, 2012–2019 ($MILLION)
Table 26 CELL LINE DEVELOPMENT MARKET SIZE FOR OTHER ANIMAL SERA, BY REGION, 2012–2019 ($MILLION)
Table 27 CELL LINE DEVELOPMENT MARKET SIZE FOR MEDIA, BY REGION, 2012–2019 ($MILLION)
Table 28 CELL LINE DEVELOPMENT MARKET SIZE FOR MEDIA, BY SEGMENT, 2012–2019 ($MILLION)
Table 29 CELL LINE DEVELOPMENT MARKET SIZE FOR MINIMUM ESSENTIAL MEDIA, BY REGION, 2012–2019 ($MILLION)
Table 30 CELL LINE DEVELOPMENT MARKET SIZE FOR REDUCED SERUM MEDIA, BY REGION, 2012–2019 ($MILLION)
Table 31 CELL LINE DEVELOPMENT MARKET SIZE FOR SERUM-FREE MEDIA, BY REGION, 2012–2019 ($MILLION)
Table 32 CELL LINE DEVELOPMENT MARKET SIZE FOR REAGENTS, BY REGION, 2012–2019 ($MILLION)
Table 33 CELL LINE DEVELOPMENT MARKET SIZE FOR REAGENTS, BY SEGMENT, 2012–2019 ($MILLION)
Table 34 CELL LINE DEVELOPMENT MARKET SIZE FOR SUPPLEMENTS & GROWTH FACTORS, BY REGION, 2012–2019 ($MILLION)
Table 35 CELL LINE DEVELOPMENT MARKET SIZE FOR BUFFERS & CHEMICALS, BY REGION, 2012–2019 ($MILLION)
Table 36 CELL LINE DEVELOPMENT MARKET SIZE FOR CELL DISSOCIATION REAGENTS, BY REGION, 2012–2019 ($MILLION)
Table 37 CELL LINE DEVELOPMENT MARKET SIZE FOR CRYOPRESERVATIVE REAGENTS, BY REGION, 2012–2019 ($MILLION)
Table 38 CELL LINE DEVELOPMENT MARKET SIZE FOR OTHER REAGENTS, BY REGION, 2012–2019 ($MILLION)
Table 39 CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 40 TYPES OF MAMMALIAN CELL LINES AND THEIR APPLICATIONS
Table 41 CELL LINE DEVELOPMENT MARKET SIZE FOR MAMMALIAN SOURCES, BY REGION, 2012–2019 ($MILLION)
Table 42 CELL LINE DEVELOPMENT MARKET SIZE FOR INSECT SOURCES, BY REGION, 2012–2019 ($MILLION)
Table 43 CELL LINE DEVELOPMENT MARKET SIZE FOR AMPHIBIAN SOURCES, BY REGION, 2012–2019 ($MILLION)
Table 44 CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 45 CELL LINE DEVELOPMENT MARKET SIZE FOR PRIMARY CELL LINES, BY REGION, 2012–2019 ($MILLION)
Table 46 CELL LINE DEVELOPMENT MARKET SIZE FOR CONTINUOUS CELL LINES, BY REGION, 2012–2019 ($MILLION)
Table 47 CELL LINE DEVELOPMENT MARKET SIZE FOR HYBRIDOMAS, BY REGION, 2012–2019 ($MILLION)
Table 48 BIOLOGICS PRODUCED USING CHO CELLS (2006-2012)
Table 49 CELL LINE DEVELOPMENT MARKET SIZE FOR RECOMBINANT CELL LINES, BY REGION, 2012–2019 ($MILLION)
Table 50 CELL LINE DEVELOPMENT APPLICATIONS MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
Table 51 CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 52 CELL LINE DEVELOPMENT MARKET SIZE FOR BIOPRODUCTION, BY REGION, 2012–2019 ($MILLION)
Table 53 CELL LINE DEVELOPMENT MARKET SIZE FOR BIOPRODUCTION, BY SEGMENT, 2012–2019 ($MILLION)
Table 54 CELL LINE DEVELOPMENT MARKET SIZE FOR DIAGNOSTICS, BY REGION, 2012–2019 ($MILLION)
Table 55 CELL LINE DEVELOPMENT MARKET SIZE FOR VACCINE PRODUCTION, BY REGION, 2012–2019 ($MILLION)
Table 56 CELL LINE DEVELOPMENT MARKET SIZE FOR RECOMBINANT PROTEIN THERAPEUTICS, BY REGION, 2012–2019 ($MILLION)
Table 57 CELL LINE DEVELOPMENT MARKET SIZE FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY REGION, 2012–2019 ($MILLION)
Table 58 CELL LINE DEVELOPMENT MARKET SIZE FOR TOXICITY TESTING, BY REGION, 2012–2019 ($MILLION)
Table 59 CELL LINE DEVELOPMENT MARKET SIZE FOR RESEARCH APPLICATIONS, BY REGION, 2012–2019 ($MILLION)
Table 60 CELL LINE DEVELOPMENT MARKET SIZE FOR DRUG DISCOVERY, BY REGION, 2012–2019 ($MILLION)
Table 61 CELL LINE DEVELOPMENT MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
Table 62 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 63 NORTH AMERICA: CELL LINE DEVELOPMENT EQUIPMENT MARKET SIZE, 2012–2019 ($MILLION)
Table 64 NORTH AMERICA: CELL LINE DEVELOPMENT MEDIA & REAGENTS MARKET SIZE, 2012–2019 ($MILLION)
Table 65 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 66 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 67 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 68 U.S.: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 69 U.S.: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 70 U.S.: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 71 U.S.: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 72 CANADA: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 73 CANADA: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 74 CANADA: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 75 CANADA: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 76 EUROPE: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 77 EUROPE: CELL LINE DEVELOPMENT EQUIPMENT MARKET SIZE, 2012–2019 ($MILLION)
Table 78 EUROPE: CELL LINE DEVELOPMENT MEDIA & REAGENTS MARKET SIZE, 2012–2019 ($MILLION)
Table 79 EUROPE: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 80 EUROPE: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 81 EUROPE: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 82 FRANCE: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 83 FRANCE: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 84 FRANCE: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 85 FRANCE: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 86 GERMANY: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 87 GERMANY: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 88 GERMANY: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 89 GERMANY: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 90 U.K.: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 91 U.K.: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 92 U.K.: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 93 U.K.: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 94 ROE: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 95 ROE: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 96 ROE: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 97 ROE: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 98 ASIA: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 99 ASIA: CELL LINE DEVELOPMENT EQUIPMENT MARKET SIZE, 2012–2019 ($MILLION)
Table 100 ASIA: CELL LINE DEVELOPMENT MEDIA & REAGENTS MARKET SIZE, 2012–2019 ($MILLION)
Table 101 ASIA: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 102 ASIA: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 103 ASIA: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 104 ROW: CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
Table 105 ROW: CELL LINE DEVELOPMENT EQUIPMENT MARKET SIZE, 2012–2019 ($MILLION)
Table 106 ROW: CELL LINE DEVELOPMENT MEDIA & REAGENTS MARKET SIZE, 2012–2019 ($MILLION)
Table 107 ROW: CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2012–2019 ($MILLION)
Table 108 ROW: CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 109 ROW: CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
Table 110 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 2011–2014
Table 111 NEW PRODUCT LAUNCHES, 2011–2013
Table 112 EXPANSIONS, 2011–2014
Table 113 ACQUISITIONS, 2011–2014
Table 114 OTHERS, 2011–2014
LIST OF FIGURES
Figure 1 CELL LINE DEVELOPMENT MARKET SEGMENTATION
Figure 2 GLOBAL CELL LINE DEVELOPMENT : RESEARCH METHODOLOGY STEPS
Figure 3 SAMPLING FRAME: PRIMARY RESEARCH
Figure 4 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 7 MARKET FORECAST METHODOLOGY
Figure 8 DATA TRIANGULATION METHODOLOGY
Figure 9 GLOBAL CELL LINE DEVELOPMENT MARKET SNAPSHOT, BY PRODUCT, 2014–2019
Figure 10 MEDIA AND REAGENTS MARKET TO WITNESS HIGHEST CAGR OF 13% FROM 2014 TO 2019
Figure 11 GLOBAL CELL LINE DEVELOPMENT MARKET SHARE, 2014
Figure 12 CELL LINE DEVELOPMENT: MARKET OVERVIEW
Figure 13 NORTH AMERICA ACCOUNTS FOR LARGEST SHARE OF MARKET; RECOMBINANT CELL LINES ACCOUNT FOR 68% OF MARKET, BY TYPE
Figure 14 ASIAN CELL LINE DEVELOPMENT MARKET TO GROW AT THE HIGHEST CAGR BETWEEN 2014 AND 2019
Figure 15 MEDIA AND REAGENTS TO COMMAND OVER 50% OF THE MARKET SHARE, 2014 VS. 2019
Figure 16 ROW IS EXPECTED TO ENTER THE EXPONENTIAL GROWTH PHASE IN THE COMING YEARS
Figure 17 INCREASING DEMAND FOR MONOCLONAL ANTIBODIES TO SPUR THE GROWTH IN THIS MARKET
Figure 18 COMPETITIVE POSITIONING, BY KEY PLAYER (2014)
Figure 19 COMPETITIVE POSITIONING, BY KEY PLAYER (2014)
Figure 20 ORGANIC AND INORGANIC GROWTH STRATEGIES
Figure 21 ORGANIC GROWTH STRATEGIES, BY KEY PLAYERS (2011–2014)
Figure 22 INORGANIC GROWTH STRATEGIES, BY KEY PLAYERS (2011–2014)
Figure 23 EVOLUTION OF CELL LINE DEVELOPMENT TECHNOLOGIES
Figure 24 COMPARATIVE TECHNOLOGY ASSESSMENT – CELL LINE DEVELOPMENT MARKET
Figure 25 THE MEDIA & REAGENTS SEGMENT IS EXPECTED TO GROW AT A FASTER PACE THAN THE EQUIPMENT SEGMENT FROM 2014 TO 2019
Figure 26 ASIA IS EXPECTED TO BE THE FASTEST-GROWING CELL LINE DEVELOPMENT MARKET AT A CAGR OF 14.6% FROM 2014 TO 2019
Figure 27 NORTH AMERICA IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE CELL LINE EQUIPMENT MARKET IN 2014
Figure 28 THE OTHER EQUIPMENT SEGMENT IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE CELL LINE EQUIPMENT MARKET IN 2014
Figure 29 REFRIGERATORS & FREEZERS SEGMENT TO ACCOUNT FOR LARGEST SHARE (70%) OF STORAGE EQUIPMENT MARKET IN 2014
Figure 30 THE REAGENTS SEGMENT IS EXPECTED TO DOMINATE THE CELL LINE DEVELOPMENT MARKET
Figure 31 NORTH AMERICA IS EXPECTED TO BE THE LARGEST REGIONAL SEGMENT OF THE CELL LINE DEVELOPMENT MARKET FOR MEDIA & REAGENTS IN 2014
Figure 32 CELL LINE DEVELOPMENT MARKET FOR SERA, BY SEGMENT
Figure 33 THE FETAL BOVINE SERA SEGMENT IS EXPECTED TO COMMAND 60% OF THE CELL LINE DEVELOPMENT MARKET, GROWING AT THE HIGHEST CAGR OF 5.8%
Figure 34 CELL LINE DEVELOPMENT MARKET FOR MEDIA, BY SEGMENT
Figure 35 MINIMAL ESSENTIAL MEDIA TO GROW AT A HIGHER RATE FROM 2014 TO 2019
Figure 36 CELL LINE DEVELOPMENT MARKET FOR REAGENTS, BY SEGMENT
Figure 37 SUPPLEMENTS & GROWTH FACTORS SEGMENT TO GROW AT THE HIGHEST CAGR (13.3%) FROM 2014 TO 2019
Figure 38 CELL LINE DEVELOPMENT MARKET, BY SOURCE
Figure 39 THE MAMMALIAN SEGMENT IS POISED TO DOUBLE IN SIZE BY 2019
Figure 40 WITH WIDE APPLICATION AREAS, MAMMALIAN SEGMENT IS EXPECTED TO HOLD 75% OF THE MARKET IN 2014
Figure 41 CELL LINE DEVELOPMENT MARKET, BY TYPE
Figure 42 THE RECOMBINANT CELL LINES SEGMENT IS EXPECTED TO ACCOUNT FOR 68% (2014) OF THE CELL LINE DEVELOPMENT MARKET, BY TYPE
Figure 43 HYBRIDOMAS IS THE FASTEST-GROWING SEGMENT OF THE CELL LINE DEVELOPMENT MARKET, BY TYPE
Figure 44 CELL LINE DEVELOPMENT APPLICATIONS MARKET, 2014–2019
Figure 45 ASIA IS THE FASTEST-GROWING REGION IN THE GLOBAL CELL LINE DEVELOPMENT APPLICATIONS MARKET
Figure 46 CELL LINE DEVELOPMENT MARKET, BY APPLICATION
Figure 47 RECOMBINANT PROTEIN THERAPEUTICS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF 60% (2014) AND IS GROWING AT THE HIGHEST CAGR OF 13.5%
Figure 48 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE GLOBAL CELL LINE DEVELOPMENT MARKET
Figure 49 U.S. WILL BE THE FASTEST-GROWING COUNTRY OF THE CELL LINE DEVELOPMENT MARKET IN NORTH AMERICA
Figure 50 GERMANY TO BE THE FASTEST-GROWING COUNTRY OF THE CELL LINE DEVELOPMENT MARKET IN EUROPE
Figure 51 ASIA IS THE FASTEST-GROWING CELL LINE DEVELOPMENT MARKET
Figure 52 ROW TO ACCOUNT FOR A SHARE OF 9% OF THE GLOBAL CELL LINE DEVELOPMENT MARKET IN 2014
Figure 53 COMPANIES ADOPTED AGREEMENTS, PARTNERSHIPS, & COLLABORATIONS AS THE KEY GROWTH STRATEGY OVER THE LAST THREE YEARS
Figure 54 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2013
Figure 55 KEY GROWTH STRATEGIES OF THE GLOBAL CELL LINE DEVELOPMENT MARKET, 2011–2014
Figure 56 BATTLE FOR MARKET SHARE: AGREEMENTS, PARTNERSHIPS, & COLLABORATIONS WAS THE KEY STRATEGY
Figure 57 GEOGRAPHICAL REVENUE MIX OF TOP 5 MARKET PLAYERS
Figure 58 AMERICAN TYPE CULTURE COLLECTION: COMPANY SNAPSHOT
Figure 59 CORNING, INC.: COMPANY SNAPSHOT
Figure 60 EUROPEAN COLLECTION OF CELL CULTURES: COMPANY SNAPSHOT
Figure 61 GE HEALTHCARE: COMPANY SNAPSHOT
Figure 62 LONZA GROUP AG: COMPANY SNAPSHOT
Figure 63 SARTORIUS AG: COMPANY SNAPSHOT
Figure 64 SELEXIS SA: COMPANY SNAPSHOT
Figure 65 SIGMA-ALDRICH CORPORATION: COMPANY SNAPSHOT
Figure 66 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
Figure 67 WUXI APPTEC: COMPANY SNAPSHOT
Figure 1 CELL LINE DEVELOPMENT MARKET SEGMENTATION
Figure 2 GLOBAL CELL LINE DEVELOPMENT : RESEARCH METHODOLOGY STEPS
Figure 3 SAMPLING FRAME: PRIMARY RESEARCH
Figure 4 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 7 MARKET FORECAST METHODOLOGY
Figure 8 DATA TRIANGULATION METHODOLOGY
Figure 9 GLOBAL CELL LINE DEVELOPMENT MARKET SNAPSHOT, BY PRODUCT, 2014–2019
Figure 10 MEDIA AND REAGENTS MARKET TO WITNESS HIGHEST CAGR OF 13% FROM 2014 TO 2019
Figure 11 GLOBAL CELL LINE DEVELOPMENT MARKET SHARE, 2014
Figure 12 CELL LINE DEVELOPMENT: MARKET OVERVIEW
Figure 13 NORTH AMERICA ACCOUNTS FOR LARGEST SHARE OF MARKET; RECOMBINANT CELL LINES ACCOUNT FOR 68% OF MARKET, BY TYPE
Figure 14 ASIAN CELL LINE DEVELOPMENT MARKET TO GROW AT THE HIGHEST CAGR BETWEEN 2014 AND 2019
Figure 15 MEDIA AND REAGENTS TO COMMAND OVER 50% OF THE MARKET SHARE, 2014 VS. 2019
Figure 16 ROW IS EXPECTED TO ENTER THE EXPONENTIAL GROWTH PHASE IN THE COMING YEARS
Figure 17 INCREASING DEMAND FOR MONOCLONAL ANTIBODIES TO SPUR THE GROWTH IN THIS MARKET
Figure 18 COMPETITIVE POSITIONING, BY KEY PLAYER (2014)
Figure 19 COMPETITIVE POSITIONING, BY KEY PLAYER (2014)
Figure 20 ORGANIC AND INORGANIC GROWTH STRATEGIES
Figure 21 ORGANIC GROWTH STRATEGIES, BY KEY PLAYERS (2011–2014)
Figure 22 INORGANIC GROWTH STRATEGIES, BY KEY PLAYERS (2011–2014)
Figure 23 EVOLUTION OF CELL LINE DEVELOPMENT TECHNOLOGIES
Figure 24 COMPARATIVE TECHNOLOGY ASSESSMENT – CELL LINE DEVELOPMENT MARKET
Figure 25 THE MEDIA & REAGENTS SEGMENT IS EXPECTED TO GROW AT A FASTER PACE THAN THE EQUIPMENT SEGMENT FROM 2014 TO 2019
Figure 26 ASIA IS EXPECTED TO BE THE FASTEST-GROWING CELL LINE DEVELOPMENT MARKET AT A CAGR OF 14.6% FROM 2014 TO 2019
Figure 27 NORTH AMERICA IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE CELL LINE EQUIPMENT MARKET IN 2014
Figure 28 THE OTHER EQUIPMENT SEGMENT IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE CELL LINE EQUIPMENT MARKET IN 2014
Figure 29 REFRIGERATORS & FREEZERS SEGMENT TO ACCOUNT FOR LARGEST SHARE (70%) OF STORAGE EQUIPMENT MARKET IN 2014
Figure 30 THE REAGENTS SEGMENT IS EXPECTED TO DOMINATE THE CELL LINE DEVELOPMENT MARKET
Figure 31 NORTH AMERICA IS EXPECTED TO BE THE LARGEST REGIONAL SEGMENT OF THE CELL LINE DEVELOPMENT MARKET FOR MEDIA & REAGENTS IN 2014
Figure 32 CELL LINE DEVELOPMENT MARKET FOR SERA, BY SEGMENT
Figure 33 THE FETAL BOVINE SERA SEGMENT IS EXPECTED TO COMMAND 60% OF THE CELL LINE DEVELOPMENT MARKET, GROWING AT THE HIGHEST CAGR OF 5.8%
Figure 34 CELL LINE DEVELOPMENT MARKET FOR MEDIA, BY SEGMENT
Figure 35 MINIMAL ESSENTIAL MEDIA TO GROW AT A HIGHER RATE FROM 2014 TO 2019
Figure 36 CELL LINE DEVELOPMENT MARKET FOR REAGENTS, BY SEGMENT
Figure 37 SUPPLEMENTS & GROWTH FACTORS SEGMENT TO GROW AT THE HIGHEST CAGR (13.3%) FROM 2014 TO 2019
Figure 38 CELL LINE DEVELOPMENT MARKET, BY SOURCE
Figure 39 THE MAMMALIAN SEGMENT IS POISED TO DOUBLE IN SIZE BY 2019
Figure 40 WITH WIDE APPLICATION AREAS, MAMMALIAN SEGMENT IS EXPECTED TO HOLD 75% OF THE MARKET IN 2014
Figure 41 CELL LINE DEVELOPMENT MARKET, BY TYPE
Figure 42 THE RECOMBINANT CELL LINES SEGMENT IS EXPECTED TO ACCOUNT FOR 68% (2014) OF THE CELL LINE DEVELOPMENT MARKET, BY TYPE
Figure 43 HYBRIDOMAS IS THE FASTEST-GROWING SEGMENT OF THE CELL LINE DEVELOPMENT MARKET, BY TYPE
Figure 44 CELL LINE DEVELOPMENT APPLICATIONS MARKET, 2014–2019
Figure 45 ASIA IS THE FASTEST-GROWING REGION IN THE GLOBAL CELL LINE DEVELOPMENT APPLICATIONS MARKET
Figure 46 CELL LINE DEVELOPMENT MARKET, BY APPLICATION
Figure 47 RECOMBINANT PROTEIN THERAPEUTICS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF 60% (2014) AND IS GROWING AT THE HIGHEST CAGR OF 13.5%
Figure 48 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE GLOBAL CELL LINE DEVELOPMENT MARKET
Figure 49 U.S. WILL BE THE FASTEST-GROWING COUNTRY OF THE CELL LINE DEVELOPMENT MARKET IN NORTH AMERICA
Figure 50 GERMANY TO BE THE FASTEST-GROWING COUNTRY OF THE CELL LINE DEVELOPMENT MARKET IN EUROPE
Figure 51 ASIA IS THE FASTEST-GROWING CELL LINE DEVELOPMENT MARKET
Figure 52 ROW TO ACCOUNT FOR A SHARE OF 9% OF THE GLOBAL CELL LINE DEVELOPMENT MARKET IN 2014
Figure 53 COMPANIES ADOPTED AGREEMENTS, PARTNERSHIPS, & COLLABORATIONS AS THE KEY GROWTH STRATEGY OVER THE LAST THREE YEARS
Figure 54 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2013
Figure 55 KEY GROWTH STRATEGIES OF THE GLOBAL CELL LINE DEVELOPMENT MARKET, 2011–2014
Figure 56 BATTLE FOR MARKET SHARE: AGREEMENTS, PARTNERSHIPS, & COLLABORATIONS WAS THE KEY STRATEGY
Figure 57 GEOGRAPHICAL REVENUE MIX OF TOP 5 MARKET PLAYERS
Figure 58 AMERICAN TYPE CULTURE COLLECTION: COMPANY SNAPSHOT
Figure 59 CORNING, INC.: COMPANY SNAPSHOT
Figure 60 EUROPEAN COLLECTION OF CELL CULTURES: COMPANY SNAPSHOT
Figure 61 GE HEALTHCARE: COMPANY SNAPSHOT
Figure 62 LONZA GROUP AG: COMPANY SNAPSHOT
Figure 63 SARTORIUS AG: COMPANY SNAPSHOT
Figure 64 SELEXIS SA: COMPANY SNAPSHOT
Figure 65 SIGMA-ALDRICH CORPORATION: COMPANY SNAPSHOT
Figure 66 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
Figure 67 WUXI APPTEC: COMPANY SNAPSHOT
